Surge In Cancer Cases Fueling Growth Due To Rising Need For Supportive Therapy Is Supporting Development Across The Filgrastim Biosimilars Market

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

How Will The Market Size Of The Filgrastim Biosimilars Market Progress Through 2030?

The filgrastim biosimilars market size has seen swift expansion in recent years. It is forecast to rise from $1.19 billion in 2025 to $1.33 billion in 2026, achieving a compound annual growth rate (CAGR) of 11.5%. This historical growth is attributable to the high cost associated with originator filgrastim, an escalating prevalence of cancer and various blood disorders, constrained availability of biologics in developing regions, the development of hospital infrastructure, and the early regulatory endorsements for biosimilars.

The filgrastim biosimilars market size is anticipated to grow significantly in the coming years, reaching $2.09 billion in 2030 at a compound annual growth rate (CAGR) of 11.9%. This expansion during the forecast period is driven by factors such as the introduction of next-generation filgrastim biosimilars, the broadening of contract manufacturing partnerships, increasing adoption in chronic and autoimmune diseases, rising government support and reimbursement policies, and the development of patient-centric distribution and delivery models. Key trends expected over the forecast duration include the increasing utilization of filgrastim biosimilars in oncology and blood disorder treatments, the expansion of contract manufacturing organizations for biosimilar production, a greater use of in-house vertically integrated manufacturing facilities, a growing preference for hospital and retail pharmacy distribution channels, and a focus on cost-effective biologics and enhanced access in emerging markets.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=4016&type=smp

Which Drivers Are Advancing The Filgrastim Biosimilars Market Growth?

An escalating incidence of cancer is anticipated to fuel the expansion of the filgrastim biosimilars market moving forward. Cancer is characterized as a collection of diseases defined by the uncontrolled proliferation and dispersion of atypical cells throughout the body, triggered by genetic mutations that disrupt normal cellular regulation. The growing occurrence of cancer is partially due to an aging population, as individuals live longer and face a greater likelihood of developing genetic mutations that can lead to cancer. Filgrastim biosimilars assist cancer patients by boosting the production of white blood cells, thereby decreasing the risk of chemotherapy-induced neutropenia and allowing for safer, more continuous cancer treatment. For example, in October 2025, the National Health Service (NHS), a UK-based government health agency, recorded 354,820 new cancer diagnoses in 2023, averaging 972 per day, which marks an increase of 8,605 compared to 2022. Therefore, the increasing incidence of cancer is propelling the filgrastim biosimilars market.

Which Segment-Based Categories Are Covered In The Filgrastim Biosimilars Market?

The filgrastim biosimilars market covered in this report is segmented –

1) By Type Of Manufacturing: In-House Manufacturing, Contract Manufacturing organization

2) By Application: Oncology, Chronic And Autoimmune Diseases, Blood Disorders, Other Applications

3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

Subsegments:

1) By In-House Manufacturing: Proprietary In-House Manufacturing Facilities, Company-Owned Production Plants, Vertically Integrated Manufacturing

2) By Contract Manufacturing Organization: Full-Service Contract Manufacturing, Fill and Finish Services, API (Active Pharmaceutical Ingredient) Manufacturing, Specialized Biosimilar Manufacturing Services

Which Trends Are Affecting The Filgrastim Biosimilars Market Framework?

Major companies in the filgrastim biosimilar market are developing innovative products utilizing advanced technologies, such as recombinant DNA technology, for biosimilar production. Recombinant DNA technology involves the creation of hybrid or chimeric DNA by inserting a foreign genetic sequence into an organism’s DNA. For instance, in May 2023, Amneal Pharmaceuticals, a US-based pharmaceutical company, launched FYLNETRA (pegfilgrastim-pbbk), a biosimilar to Amgen’s NEULASTA, in the United States. This product is indicated for the treatment and prevention of febrile neutropenia. It functions by promoting the expansion and specialization of neutrophils from dedicated precursor cells, initiating their maturation, and improving the viability and efficiency of fully developed neutrophils, leading to dosage-dependent increases in neutrophil counts. The introduction of Fylnetra contributes to the next generation of affordable medicines and enhances access for patients, providers, and payors.

Which Key Players Are Active In The Filgrastim Biosimilars Market?

Major companies operating in the filgrastim biosimilars market are Teva Pharmaceutical Industries Ltd, Biocon Limited, Intas Biopharmaceuticals, Dr. Reddy’s Laboratories, Cadila Healthcare Ltd, Reliance Life Science Pvt. Ltd, Gennova Biopharmaceuticals (Emcure), Sandoz Pty Ltd, Mylan, Lupin Limited, Coherus Biosciences Inc., Tonghua Dongbaoare, Adello Biologics, Apobiologix (Apotex), Hospira, Tanvex BioPharma.

Access The Complete Filgrastim Biosimilars Market Report:

https://www.thebusinessresearchcompany.com/report/filgrastim-biosimilar-global-market-report

Which Region Stands As The Largest Contributor To The Filgrastim Biosimilars Market?

North America was the largest region in the filgrastim biosimilar markets market in 2025. Middle East is expected to be the fastest growing region in the global filgrastim biosimilar markets market during the forecast period. The regions covered in the filgrastim biosimilars market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Filgrastim Biosimilars Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=4016&type=smp

Browse Through More Reports Similar to the Global Filgrastim Biosimilars Market 2026, By The Business Research Company

Neutropenia Biologic Drug Treatments Market Report 2026

https://www.thebusinessresearchcompany.com/report/neutropenia-biologic-drug-treatments-global-market-report

G Csf Market Report 2026

https://www.thebusinessresearchcompany.com/report/g-csf-global-market-report

Pegfilgrastim Biosimilar Market Report 2026

https://www.thebusinessresearchcompany.com/report/pegfilgrastim-biosimilar-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795